


## PAQ

Cat. No.:	HY-138806
CAS No.:	943902-10-1
Molecular Formula:	C <sub>14</sub> H <sub>11</sub> N <sub>3</sub>
Molecular Weight:	221.26
Target:	Others
Pathway:	Others
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



## BIOLOGICAL ACTIVITY

<b>Description</b>	PAQ (Compound 4c) is a quinoxaline derivative. PAQ is an orally active neuroprotective agent, which targets dopamine (DA) neurons and activates reticulum endoplasmic ryanodine receptor (RyR) channels, without effects on glia cells <sup>[1]</sup> .	
<b>In Vivo</b>	PAQ (25-50 mg/kg, p.o., 11 days) exhibits a neuroprotective effect on SN DA neurons in C57BL/6 mice model of PD <sup>[1]</sup> . MCE has not independently confirmed the accuracy of these methods. They are for reference only.	
	Animal Model:	Neurotoxin MPTP (HY-15608) induced dopamine depletion in Parkinson disease in C57BL/6 mice <sup>[1]</sup>
	Dosage:	25-50 mg/kg
	Administration:	p.o. for 11 days
	Result:	Reduced levels of striatal DA and DOPAC+HVA/DA ratios. Maintained dendritic network in midbrain tissue sections in TH <sup>+</sup> neurons.

## REFERENCES

[1]. Le Douaron G, et al., New 6-Aminoquinoxaline Derivatives with Neuroprotective Effect on Dopaminergic Neurons in Cellular and Animal Parkinson Disease Models. J Med Chem. 2016 Jul 14;59(13):6169-86.

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA